Observational studyAIDS (London, England)2024
Effects of COVID-19 mRNA vaccination on HIV viremia and reservoir size.
Observational study in AIDS (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 14 citations in OpenAlex.
- Phase 2 Trial of Long-Acting Cabotegravir and VRC07-523LS for Viral Suppression in Adults With HIV-1: ACTG A5357.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Trial
- HIV-1 viral load and reservoir size remain stable following SARS-CoV-2 mRNA vaccination in people with HIV.HIV medicine · 2026Article
- Durable but impaired humoral and cellular immune responses against monkeypox virus in people with HIV over 18 months.Journal of translational medicine · 2026Article
- Potential Impact of SARS-CoV-2 Spike Protein on HIV-1 Reservoir in People Living with HIV.Viruses · 2026Review
- Dynamics of HIV reservoirs following repeated anti-SARS-CoV-2 vaccination.Frontiers in immunology · 2026Review
- Adjuvants MPLA and SMNP induce antiviral immunity and indirectly revert HIV-1 latency.PloS one · 2026Article
- Effects of inactivated COVID-19 vaccination on HIV viremia and reservoir size: a longitudinal cohort study.BMC infectious diseases · 2025Observational
- Tolerance of Inactivated SARS-CoV-2 Vaccine for People Living with HIV: A Real-World Evidence Analysis from a Retrospective Cohort Study.Journal of epidemiology and global health · 2025Article
- The Effect of SARS-CoV-2 Vaccination on HIV Viral Load in Patients Under Bictegravir/Tenofovir Alafenamide/Emtricitabine Therapy: A Retrospective Observational Study.Healthcare (Basel, Switzerland) · 2025Article
- Safety Profile of COVID-19 Vaccines in HIV Patients Undergoing ART and Their Impact on Immune Recovery and HIV Reservoirs.Infectious diseases & immunity · 2024Article
Corrections and comments
- Commented on by
- Update of
Authors and funding
20 authors at 5 institutions in 2 countries.
Funding
Abstract
objectiveThe immunogenic nature of coronavirus disease 2019 (COVID-19) mRNA vaccines led to some initial concern that these could stimulate the HIV reservoir. We analyzed changes in plasma HIV loads (pVL) and reservoir size following COVID-19 mRNA vaccination in 62 people with HIV (PWH) receiving antiretroviral therapy (ART), and analyzed province-wide trends in pVL before and after the mass vaccination campaign.
designLongitudinal observational cohort and province-wide analysis.
methodsSixty-two participants were sampled prevaccination, and one month after their first and second COVID-19 immunizations. Vaccine-induced anti-SARS-CoV-2-Spike antibodies in serum were measured using the Roche Elecsys Anti-S assay. HIV reservoirs were quantified using the intact proviral DNA assay; pVL were measured using the cobas 6800 (lower limit of quantification: 20 copies/ml). The province-wide analysis included all 290 401 pVL performed in British Columbia, Canada between 2012 and 2022.
resultsPrevaccination, the median intact reservoir size was 77 [interquartile range (IQR): 20-204] HIV copies/million CD4 + T-cells, compared to 74 (IQR: 27-212) and 65 (IQR: 22-174) postfirst and -second dose, respectively (all comparisons P > 0.07). Prevaccination, 82% of participants had pVL <20 copies/ml (max: 110 copies/ml), compared to 79% postfirst dose (max: 183 copies/ml) and 85% postsecond dose (max: 79 copies/ml) ( P > 0.4). There was no evidence that the magnitude of the vaccine-elicited anti-SARS-CoV-2-Spike immune response influenced pVL nor changes in reservoir size ( P > 0.6). We found no evidence linking the COVID-19 mass vaccination campaign to population-level increases in detectable pVL frequency among all PWH in the province, nor among those who maintained pVL suppression on ART.
conclusionWe found no evidence that COVID-19 mRNA vaccines induced changes in HIV reservoir size nor plasma viremia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.